A Phase I/II Study of 166Ho-DOTMP With Peripheral Blood Progenitor Cell Support for Refractory or Recurrent Ewing's Sarcoma Family of Tumors With Bone Disease.

Trial Profile

A Phase I/II Study of 166Ho-DOTMP With Peripheral Blood Progenitor Cell Support for Refractory or Recurrent Ewing's Sarcoma Family of Tumors With Bone Disease.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Nov 2011

At a glance

  • Drugs Holmium-166-DOTMP (Primary)
  • Indications Ewing's sarcoma; Rhabdomyosarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Nov 2011 Actual end date (1 Mar 2006) added as reported by ClinicalTrials.gov.
    • 19 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top